Information about Dr. David Shulkin and the Patient Safety Officer Society
Evernorth Will Offer a Private-Label Stelara Biosimilar in 2025
The private-label biosimilar will be available at an 80% discount off Stelara. Evernorth has not released information about which company will be producing the biosimilar.
Read More
Can Outcomes-Based Agreements Work for Weight Loss Drugs?
Outcomes-based agreements can take away clinical uncertainties, so payers have a guarantee that they're not spending money on something that’s not going to work.
Analysis: Consumer Out-of-Pocket Drug Costs Rise Faster than Insurer Costs
The growth of out-of-pocket and insurer/negotiated prices paralleled one another until 2016 when negotiated and insurer prices began declining
FDA New Drug Application Accepted for Sebetralstat to Treat Hereditary Angioedema
Sebetralstat would be the first oral, on-demand treatment for hereditary angioedema if approved.
Capital Rx Launches Program for Self-Funded Employers
The new program provides large employers with access to Capital Rx’s technology platform for claim adjudication, invoicing, and reimbursement.
MedImpact Selects Simlandi and an Unbranded Humira Biosimilar
MedImpact is not requiring patients currently taking Humira to switch, and all three products are on a preferred tier.